{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T01:17:10Z","timestamp":1790731030548,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"GP-Pharm S.A., Spain"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.clinthera.2019.01.004","type":"journal-article","created":{"date-parts":[[2019,2,9]],"date-time":"2019-02-09T20:44:24Z","timestamp":1549745064000},"page":"412-425","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["A New Sustained-release, 3-Month Leuprolide Acetate\u00a0Formulation Achieves and Maintains Castrate Concentrations of Testosterone in Patients With Prostate Cancer"],"prefix":"10.1016","volume":"41","author":[{"given":"Neal D.","family":"Shore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00edlvia","family":"Guerrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa Ma","family":"Sanahuja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"Gamb\u00fas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Parente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2019.01.004_bib1","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clinthera.2019.01.004_bib2","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1185\/030079907X187973","article-title":"LHRH agonists in prostate cancer: frequency of treatment, serum testosterone measurement and castrate level: consensus opinion from a roundtable discussion","volume":"23","author":"de Jong","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2019.01.004_bib3","first-page":"22","article-title":"Utility of LHRH antagonists for advanced prostate cancer","volume":"21","author":"Moul","year":"2014","journal-title":"Can J Urol"},{"key":"10.1016\/j.clinthera.2019.01.004_bib4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0090-4295(02)02393-2","article-title":"Hormonal therapy: historical perspective to future directions","volume":"61","author":"Mcleod","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.clinthera.2019.01.004_bib5","doi-asserted-by":"crossref","first-page":"566","DOI":"10.7326\/0003-4819-132-7-200004040-00009","article-title":"Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis","volume":"132","author":"Seidenfeld","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2019.01.004_bib6","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1046\/j.1464-410x.2000.00528.x","article-title":"Differential response of prostate specific antigen to testosterone surge after luteinizing hormone-releasing hormone analogue in prostate cancer and benign prostatic hyperplasia","volume":"85","author":"Agarwal","year":"2000","journal-title":"BJU Int"},{"key":"10.1016\/j.clinthera.2019.01.004_bib7","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/S0196-9781(99)00130-8","article-title":"Luteinizing hormone-releasing hormone analogs: their impact on the control of tumorigenesis","volume":"20","author":"Schally","year":"1999","journal-title":"Peptides"},{"key":"10.1016\/j.clinthera.2019.01.004_bib8","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1517\/13543784.10.4.709","article-title":"LHRH analogues as anticancer agents: pituitary and extrapituitary sites of action","volume":"10","author":"Limonta","year":"2001","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.clinthera.2019.01.004_bib9","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1038\/bjc.2011.385","article-title":"Androgen deprivation therapy as adjuvant\/neoadjuvant to radiotherapy for high-risk localised and locally advanced prostate cancer: recent developments","volume":"105","author":"Payne","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clinthera.2019.01.004_bib10","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1007\/s40265-013-0107-2","article-title":"Rationale for and review of neoadjuvant therapy prior to radical prostatectomy for patients with high-risk prostate cancer","volume":"73","author":"McKay","year":"2013","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2019.01.004_bib11","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/clpt.1984.186","article-title":"Endocrine and clinical effects of leuprolide in prostatic cancer","volume":"36","author":"Vance","year":"1984","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2019.01.004_bib12","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2165\/00002512-199101060-00008","article-title":"Leuprorelin: a review of its pharmacology and therapeutic use in prostatic disorders","volume":"1","author":"Chrisp","year":"1991","journal-title":"Drugs Aging"},{"key":"10.1016\/j.clinthera.2019.01.004_bib13","first-page":"68","article-title":"Clinical study of leuprolide depot formulation in the treatment of advanced prostate cancer.\u00a0The Leuprolide Study Group","volume":"143","author":"Sharifi","year":"1990","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clinthera.2019.01.004_bib14","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1001\/jama.294.2.238","article-title":"Androgen deprivation therapy for prostate cancer","volume":"294","author":"Sharifi","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2019.01.004_bib15","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/S0149-2918(96)80215-3","article-title":"Leuprolide acetate 22.5 mg 12-week depot formulation in the treatment of patients with advanced prostate cancer","volume":"18","author":"Sharifi","year":"1996","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2019.01.004_bib16","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1159\/000282865","article-title":"Efficacy and safety of leuprorelin acetate depot for prostate cancer","volume":"56","author":"Kienle","year":"1996","journal-title":"Urol Int"},{"key":"10.1016\/j.clinthera.2019.01.004_bib17","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1159\/000056547","article-title":"Leuprorelin three-month depot in the treatment of advanced and metastatic prostate cancer: long-term follow-up results","volume":"60","author":"Jocham","year":"1998","journal-title":"Urol Int"},{"key":"10.1016\/j.clinthera.2019.01.004_bib18","first-page":"1001","article-title":"Serum testosterone suppression and potential for agonistic stimulation during chronic treatment with monthly and 3-month depot formulations of leuprolide acetate for advanced prostate cancer","volume":"168","author":"Sharifi","year":"2002","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clinthera.2019.01.004_bib19","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1016\/S0149-2918(02)80087-X","article-title":"A\u00a0six-month, open-label study assessing a new formulation of leuprolide 7.5 mg for suppression of testosterone in patients with prostate cancer","volume":"24","author":"Perez-marreno","year":"2002","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2019.01.004_bib20","first-page":"1199","article-title":"A\u00a0clinical study of 22.5 mg. La-2550: a new subcutaneous depot delivery system for leuprolide acetate for the treatment of prostate cancer","volume":"168","author":"Chu","year":"2002","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clinthera.2019.01.004_bib21","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.clinthera.2010.04.013","article-title":"Effectiveness, pharmacokinetics, and safety of a new sustained-release leuprolide acetate 3.75-mg depot formulation for testosterone suppression in patients with prostate cancer: a phase III, open-label, international multicenter study","volume":"32","author":"Marberger","year":"2010","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2019.01.004_bib22","doi-asserted-by":"crossref","first-page":"274","DOI":"10.4103\/0974-7788.76794","article-title":"Understanding survival analysis: Kaplan-Meier estimate","volume":"1","author":"Kishore","year":"2010","journal-title":"Int J Ayurveda Res"},{"key":"10.1016\/j.clinthera.2019.01.004_bib23","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1159\/000474238","article-title":"Randomized open labelled comparative study of the efficacy, safety and tolerability of leuprorelin acetate 1M and 3M depot in patients with advanced prostatic cancer","volume":"30","author":"Wechsel","year":"1996","journal-title":"Eur Urol"},{"key":"10.1016\/j.clinthera.2019.01.004_bib24","doi-asserted-by":"crossref","first-page":"477","DOI":"10.5114\/aoms.2014.43743","article-title":"Efficacy and tolerability of 1- and 3-month leuprorelin acetate depot formulations (Eligard(\u00ae)\/Depo-Eligard(\u00ae)) for advanced prostate cancer in daily practice: a Belgian prospective non-interventional study","volume":"10","author":"Braeckman","year":"2014","journal-title":"Arch Med Sci"},{"key":"10.1016\/j.clinthera.2019.01.004_bib25","series-title":"NCCN Clinical Practice Guidelines in Oncology Prostate Cancer Version 2.2017","author":"NCCN","year":"2017"},{"key":"10.1016\/j.clinthera.2019.01.004_bib26","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S0090-4295(00)00793-7","article-title":"Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making","volume":"56","author":"Oefelein","year":"2000","journal-title":"Urology"},{"key":"10.1016\/j.clinthera.2019.01.004_bib27","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1200\/JCO.2014.58.2973","article-title":"Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT","volume":"33","author":"Klotz","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clinthera.2019.01.004_bib28","first-page":"S10","article-title":"Flare associated with LHRH-agonist therapy","volume":"3","author":"Thompson","year":"2001","journal-title":"Rev Urol"},{"key":"10.1016\/j.clinthera.2019.01.004_bib29","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0090-4295(01)01235-3","article-title":"Is the flare phenomenon clinically significant?","volume":"58","author":"Bubley","year":"2001","journal-title":"Urology"},{"key":"10.1016\/j.clinthera.2019.01.004_bib30","first-page":"52","article-title":"Effective testosterone suppression for prostate cancer: is there a best castration therapy?","volume":"11","author":"Gomella","year":"2009","journal-title":"Rev Urol"},{"key":"10.1016\/j.clinthera.2019.01.004_bib31","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.eursup.2005.08.004","article-title":"How good do current LHRH agonists control testosterone? can this be improved with Eligard\u00ae?","volume":"4","author":"Tombal","year":"2005","journal-title":"Eur Urol Suppl"},{"key":"10.1016\/j.clinthera.2019.01.004_bib32","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.eururo.2016.08.003","article-title":"EAU-ESTRO-SIOG guidelines on prostate cancer, part I: screening, diagnosis, and local treatment with curative intent","volume":"71","author":"Mottet","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.clinthera.2019.01.004_bib33","series-title":"NDA-22437 Administrative and Correspondence Documents","author":"Center for Drug Evaluation and Research","year":"2010"},{"key":"10.1016\/j.clinthera.2019.01.004_bib34","first-page":"38.e17","article-title":"Serum testosterone levels after medical or surgical androgen deprivation: a comprehensive review of the literature","volume":"32","author":"Nishiyama","year":"2014","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"10.1016\/j.clinthera.2019.01.004_bib35","first-page":"1971","article-title":"Adrenocorticotropic hormone is involved in regulation of androgen synthesis in men receiving androgen deprivation therapy for localized prostate cancer","volume":"184","author":"Takizawa","year":"2010","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clinthera.2019.01.004_bib36","series-title":"US-American NCCN-guideline on prostate cancer","year":"2015"},{"key":"10.1016\/j.clinthera.2019.01.004_bib37","first-page":"63","article-title":"Androgen deprivation therapy for prostate cancer: long-term safety and patient outcomes","volume":"5","author":"Ahmadi","year":"2014","journal-title":"Patient Relat Outcome Meas"},{"key":"10.1016\/j.clinthera.2019.01.004_bib38","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.clgc.2013.05.004","article-title":"Luteinizing hormone-releasing hormone agonists: a quick reference for prevalence rates of potential adverse effects","volume":"11","author":"Walker","year":"2013","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clinthera.2019.01.004_bib39","first-page":"37","article-title":"For prostate cancer","volume":"7","author":"Kumar","year":"2005","journal-title":"Rev Urol"},{"key":"10.1016\/j.clinthera.2019.01.004_bib40","unstructured":"FDA-Label-ELIGARD\u00ae. (leuprolide acetate for injectable suspension). Revised 02\/2016."}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291819300086?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291819300086?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:49:48Z","timestamp":1758962988000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291819300086"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S0149291819300086"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2019.01.004","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A New Sustained-release, 3-Month Leuprolide Acetate\u00a0Formulation Achieves and Maintains Castrate Concentrations of Testosterone in Patients With Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2019.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}